Tenaya Therapeutics is an emerging biotech company focused on gene therapy candidates targeting complex genetic cardiovascular diseases such as hypertrophic and arrhythmogenic right ventricular cardiomyopathies. The company remains pre-revenue, incurring significant net losses that have moderately improved in recent years alongside controlled cash burn. Its pipeline centers on TN-201 and TN-401, advanced through preclinical to early clinical stages, complemented by a newly announced collaboration with Alnylam Pharmaceuticals to leverage RNA interference expertise for novel target discovery. Despite robust liquidity and strategic partnerships, Tenaya faces substantial regulatory, manufacturing scale-up, and capital financing risks typical of gene therapy developers. Ongoing milestones, regulatory progress, and funding rounds will be critical to monitor.